Physician profile
Travis James
NPI 1477818920
$437,411.14
in general payments reported to CMS, 2019-2025
31 companies · $143K in 2025
The $143K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $30K · 2021: $47K · 2022: $49K · 2023: $54K · 2024: $44K · 2025: $143K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $216K · Travel and Lodging: $14K · Consulting Fee: $5,920 · Food and Beverage: $5,550 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $215,728.00 |
| Travel and Lodging | $14,376.88 |
| Consulting Fee | $5,920.00 |
| Food and Beverage | $5,549.72 |
| Education | $213.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $331,854.86 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Ucb, INC. | $79,646.82 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $17,596.22 | 2019-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $3,224.12 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $2,435.80 | 2019-2025 | Cosentyx |
| Abbvie INC. | $524.46 | 2019-2024 | |
| Janssen Biotech, INC. | $377.93 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $208.48 | 2019-2023 | Dupixent |
| Arcutis Biotherapeutics, INC. | $151.58 | 2023-2025 | Zoryve |
| Allergan, INC. | $140.86 | 2019 | |
| Leo Pharma INC. | $135.96 | 2022-2024 | Adbry |
| Pfizer INC. | $121.85 | 2019-2020 | |
| Merz North America, INC. | $109.47 | 2021 | |
| Amgen INC. | $102.67 | 2019-2023 | Otezla |
| Dermavant Sciences, INC. | $92.77 | 2023-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $84.36 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $82.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Incyte Corporation | $65.47 | 2021-2023 | Opzelura |
| Prugen, INC. Pharmaceuticals | $60.47 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $59.10 | 2019-2021 | |
| Biofrontera INC. | $57.72 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sun Pharmaceutical Industries INC. | $51.55 | 2019-2020 | |
| Almirall LLC | $29.31 | 2025 | Seysara |
| Revance Therapeutics, INC. | $24.62 | 2025 | Daxxify |
| Taro Pharmaceuticals USA, INC. | $22.31 | 2019 | |
| Celgene Corporation | $20.81 | 2019 | |
| Genentech USA, INC. | $15.64 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.30 | 2023 | Ycanth |
| Smith+Nephew, INC. | $13.93 | 2021 | |
| Organon LLC | $5.01 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.